IDXX
$586.98
IDEXX Laboratories, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Co...
Recent News
A Look At Idexx Laboratories (IDXX) Valuation As Recent Share Price Momentum Softens
Event context and recent price performance IDEXX Laboratories (IDXX) has not been driven by a single headline event recently. However, its share price moves provide fresh context. The stock is around US$573.82, with a 1 day return near flat. See our latest analysis for IDEXX Laboratories. Recent trading has been weaker, with a 7 day share price return of around a 6% decline and a 30 day share price return of about an 8.8% decline. However, the 1 year total shareholder return of roughly 35.9%...
Is IDEXX Laboratories Stock Outperforming the S&P 500?
Despite outperforming the broader S&P 500 Index over the past year, analysts maintain a cautiously optimistic outlook on IDEXX Laboratories’ future prospects.
Is IDEXX Laboratories, Inc. (IDXX) A Good Stock To Buy?
Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on IDXX. IDEXX Laboratories, Inc.’s share was trading at $571.21 as of March 12th. IDXX’s trailing and forward P/E were 45.91 and 42.02 . respectively according to Yahoo […]
Bamco Expands FactSet Stake to $838 Million as Financial Data Platform Drives Recurring Revenue
FactSet provides financial data, analytics, and workflow software used by investment professionals worldwide. Because its platform is embedded in research and portfolio-management systems, the company generates recurring subscription revenue tied to the day-to-day operations of investment firms.
IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It?
IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.